A rapidly advancing area of biomedical innovation is shining a spotlight on miR-128-3p, a small yet powerful molecule with the potential to reshape how diseases—especially cancer—are detected, monitored, and treated. This microRNA, part of a broader class of non-coding RNAs, plays a critical role in regulating gene activity and maintaining cellular homeostasis.
What makes miR-128-3p particularly significant is its ability to influence a wide range of biological processes, including cell proliferation, immune regulation, metabolic balance, and tumor development. By binding to target genetic material, it can precisely control how genes are expressed, acting as a molecular regulator that determines whether cells function normally or shift toward disease.
This molecule is widely expressed across multiple tissues, including the brain, heart, liver, and lungs, highlighting its importance in overall physiology. Beyond cancer, it is also involved in conditions related to inflammation, metabolic disorders, and neurological function, reinforcing its broad impact on human health.
One of the most striking features of miR-128-3p is its dual role in cancer biology. In some contexts, it acts as a tumor suppressor, limiting cancer cell growth, migration, and invasion. In other settings, it can function as an oncogenic factor, promoting tumor progression and survival. This context-dependent behavior reflects the complexity of cancer and presents new opportunities for highly targeted therapeutic approaches.
The molecule is also gaining attention as a promising diagnostic biomarker. Its detectable presence in biological samples and its stability make it well-suited for non-invasive testing, enabling earlier detection and more precise disease monitoring. These qualities position it as a valuable tool for improving diagnostic accuracy and patient management.
In addition to its diagnostic potential, miR-128-3p plays an important role in treatment response. It can influence how cancer cells respond to therapies, contributing to either drug sensitivity or treatment resistance. This makes it a key factor in the development of personalized medicine, where therapies are tailored to the molecular characteristics of each patient.
As understanding of this molecule continues to expand, miR-128-3p is emerging as a central player in next-generation healthcare. Its ability to connect gene regulation, disease progression, and therapeutic response underscores its potential to drive more precise, effective, and individualized strategies for managing complex diseases.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4 |Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Lingzi Zheng, Sheng Yan, Jinling Zhang, Weisen Ning, Xiaoliu Liu, Xiaomei Wang, Ling Hu, Diverse functional roles of miR-128-3p in human diseases: Focus on its roles in human cancer, Genes & Diseases, Volume 13, Issue 3, 2026, 101736, https://doi.org/10.1016/j.gendis.2025.101736

Funding
Natural Science Foundation of Hubei, China 2023AFB1111
Open Project Fund of Hubei Key Laboratory of Embryonic Stem Cell Research (China) 2022ESOF009
Wuhan Health Commission Gene Funding Project (China) WX21C25
NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital) (China) 2024HYX001